Search
Insulin beef
go.drugbank.com/drugs/DB09456ApprovedInsulin beef has been discontinued in the US and Canada since 2017.[L10827]
Oxatomide
go.drugbank.com/drugs/DB12877ApprovedOxatomide has been used in trials studying the treatment of Muscular Dystrophy, Duchenne.
Parthenolide
go.drugbank.com/drugs/DB13063ApprovedInvestigationalParthenolide has been used in trials studying the diagnostic of Allergic Contact Dermatitis.
Butaperazine
go.drugbank.com/drugs/DB13213ApprovedButaperazine was approved in 1967 [L5143], and possibly discontinued in the 1980s [T397].
Sebelipase alfa
go.drugbank.com/drugs/DB11563ApprovedInvestigationalIt was first approved by both the FDA and EMA in 2015 and is marketed under the brand name Kanuma (Alexion Pharmaceuticals).[L39337,L39342]
Apronalide
go.drugbank.com/drugs/DB13221ApprovedApronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura [A174814].
Osugacestat
go.drugbank.com/drugs/DB12006InvestigationalOsugacestat (BMS-906024) has been used in trials studying the treatment of Cancer, Lymphoblastic Leukemia, Acute T-cell, and Precursor T-Cell Lymphoblastic Lymphoma.
Synonyms: (2R,3S)-N1-((S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide, Butanediamide, N1-((3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluorophenyl)-, (2R,3S)-Veglin
go.drugbank.com/drugs/DB05890ExperimentalVEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma
Synonyms: VEGF-ASTolazamide
go.drugbank.com/drugs/DB00839ApprovedA sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Tienilic acid
go.drugbank.com/drugs/DB04831ApprovedWithdrawnTienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension. … It was withdrawn in 1982 after case reports in the United States suggested a link between ticrynafen and hepatitis. (Manier et al., 1982)